<DOC>
	<DOCNO>NCT00790816</DOCNO>
	<brief_summary>This study design provide continued access lapatinib monotherapy part combination regimen cancer subject currently participate phase I trial meet study objective .</brief_summary>
	<brief_title>Continuation Study Lapatinib Monotherapy Lapatinib Combination With Other Anti-cancer Agents</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Participation Phase I lapatinib trial meet study objective . Ability understand provide write informed consent participate study . Male female great equal 18 year age . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method state protocol wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least two four week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential , negative serum pregnancy test baseline , agree use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception two week prior administration study drug throughout entire active study treatment period four week last dose study medication . Permanent discontinuation lapatinib previous study due intolerance treatment failure . Is pregnant lactate female . Is consider medically unfit study investigator result medical interview , physical exam , baseline investigation . Currently receive treatment medication list prohibited medication list protocol Has Class III IV heart failure define New York Heart Association ( NYHA ) functional classification system . Have current active hepatic biliary disease ( exception subject Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>lapatinib</keyword>
	<keyword>Combination therapy</keyword>
	<keyword>Chronic administration</keyword>
</DOC>